page-template-default,page,page-id-12,bridge-core-2.1.9,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-20.6,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.1,vc_responsive

Technology Platform

The Vaccibody Vaccine Technology Platform has the potential to overcome the challenges faced in today’s vaccine development through rational and innovative design. Vaccibody’s vaccines are based on thorough understanding of the immunological principles and physiological mechanisms:


Vaccibody vaccines can direct the immune response in an optimal manner by specifically targeting Antigen Presenting Cells (APC), known to be essential to initiate an effective immune response.


By intelligent design Vaccibody vaccines are tailored to induce the desired immune response profile for each specific disease with any given antigen.


The unique efficacy of Vaccibody’s Vaccine Technology Platform offers the possibility to develop vaccines to treat cancers. Vaccibody is currently in clinical phase I/IIa with a therapeutic HPV16-vaccine to treat precancerous cervical lesions.



Vaccibody vaccines consist of three modules, each of them serving a crucial purpose to increase efficacy. They can easily be optimally designed for a given disease based on Vaccibody’s expertise within advanced immunology. The Technology Platform is versatile and the vaccines can be delivered as DNA, RNA or Protein.

Mode of Action


The main feature of the Vaccibody Vaccine Technology Platform is the ability to attract and target Antigen Presenting Cells (APCs) which are known to be essential to initiate an effective immune response. Binding by the vaccine’s targeting module to receptors on APCs leads to rapid internalization of the Vaccibody vaccine and mediates maturation of the APC.


These events result in enhanced presentation of the internalized antigen to both Helper T cells and Cytotoxic T cells, both crucial to initiate a strong and effective immune response. Vaccibody vaccines can harbour whole, intact proteins as antigenic modules that can be recognized by B cells and stimulate antibody production with the help from Helper T cells.


The modular format of the Vaccibody vaccines facilitates an easy and fast modification of the structure to create individualized vaccines as well as off the shelf optimal Vaccines for each disease.


Therapeutic Vaccibody vaccines against cancer can be optimized for induction of Cytotoxic T cells that kill cancerous cells, see Cancer Vaccines.


Prophylactic Vaccibody vaccines against infectious diseases can be deliberately optimized for induction of protective antibody responses that neutralize the pathogen–see Infectious Diseases

Therapeutic or Prophylactic Vaccines

Compatible with individualized vaccine development

Target vaccines to Antigen Presenting Cells

Constitute potent and effective vaccines

Stimulate either or both B cell and T cell immunity

Administration as DNA, RNA or Protein